Hims & Hers Health shares drop over 4% after Q3 results miss analyst expectations

Traders Union
All News
Stocks
Hims & hers slides 4.37% today

Highlights

Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, up 49% year over year, but missed analyst estimates and recorded a $33 million net loss due to higher costs.
Subscriber count reached nearly 2.8 million but fell sequentially as management reduced marketing ahead of product and market launches, while international expansion and new partnerships continued.
Shares of Hims & Hers Health closed at $19.9, down 4.37%, trading below key moving averages with momentum indicators signaling prevailing selling pressure and an expected five-day range of $15.99 to $23.8.

Earnings shortfall widens loss amid higher costs and weaker subscriber growth

Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, a 49% year-over-year increase, but both earnings and revenue missed analyst expectations. The company recorded a net loss of $33 million, attributed to margin contraction and increased operating expenses from international growth, acquisitions, and higher fulfillment costs. Subscriber numbers approached 2.8 million, though there was a sequential decline, which management linked to a deliberate reduction in marketing ahead of new product and market launches. Expansion continued through partnerships in the weight loss segment, the Eucalyptus acquisition, and enhancements in AI-driven care, with Dr. Andrew Huberman appointed to the board and an amended FTC complaint filed over health data practices, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees a pronounced bearish trend in Hims & Hers Health Inc shares. He points to the persistent technical weakness, with prices trading under all critical moving averages and momentum indicators confirming the downside. Recent earnings missed expectations, and net losses highlight deteriorating profitability, especially as international expansion inflates costs. Sequential declines in subscribers and ongoing regulatory scrutiny add to negative sentiment and fundamental risks. "Until management addresses core margin pressures and stabilizes key business metrics, I do not expect sustainable recovery in this stock."

Viktoras Karapetjanc, expert at Traders Union, recognizes recent setbacks but sees robust fundamental progress for Hims & Hers Health. He notes strong year-over-year revenue growth and rising subscriber numbers, with strategic moves like the Eucalyptus acquisition and AI-driven care initiatives positioning the company for future expansion. Ongoing partnerships and innovation in the weight loss segment further support long-term prospects. Macro trends in digital health remain favorable, offering substantial upside despite interim volatility. "With focused execution and scalable innovations, I expect investor confidence to return and the bullish structure to reassert itself in coming quarters."

Parshwa Turakhiya, analyst, sees Hims & Hers Health locked in a volatile range after the latest earnings miss. Short-term sentiment is cautious, with momentum indicators signaling dominant selling pressure and both support and resistance levels clearly defined. Volatility remains elevated, favoring nimble, sentiment-driven trades. Trading within the bandwidth of $15.99 to $23.8, the setup may appeal to range traders if support holds. "If the stock clears $20.87 decisively, I would watch for a swift sentiment reversal — otherwise, bears retain control."

Downtrend persists with resistance from averages and broad momentum deterioration

Hims & Hers Health is trading below the 20-day, 50-day, and 200-day moving averages ($26.68, $27.95, and $26.77), signaling prevailing downward pressure across short, medium, and long-term trends. The immediate resistance is at today's high of $20.87, and the nearest support is at today's low of $19.17, with the distant overhead moving averages reinforcing the larger bearish setup. Momentum indicators, including the MACD and ADX, highlight continued selling pressure. The RSI and Stochastic RSI both remain neutral, while the CCI is in the oversold zone. Bull/Bear Power is negative, indicating that intraday action favors sellers, and the Awesome Oscillator remains aligned with ongoing bearish momentum. Intraday volatility is high at 8.87%, and the stock is trading mid-range for the session after opening with a downside gap.

Earlier, analysts noted that Hims & Hers Health faced a complex outlook as robust subscriber growth was offset by margin pressure, legal uncertainties, and bearish technical trends. The current setup strengthens this cautious view, with downside risk now more pronounced and a break below $19.17 likely to accelerate selling toward the lower end of the forecasted range.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.